Aardvark Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Tien-Li Lee and Jane Wu Lee have disclosed a combined beneficial ownership of 13.7% of Aardvark Therapeutics, Inc.'s common stock.
NASDAQ
Citadel Advisors, Citadel Securities, and Kenneth Griffin have jointly filed a Schedule 13G, disclosing a combined passive beneficial ownership of 5.6% in Aardvark Therapeutics, Inc.
NASDAQ
Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, and affiliated entities, including Dr. Xiangmin Cui, have disclosed a combined passive beneficial ownership of 18.3% in Aardvark Therapeutics, Inc.
NASDAQ
SCHEDULE 13G: Vickers Venture Fund and Principals Disclose Significant Stakes in Aardvark Therapeutics
Vickers Venture Fund VI Pte. Ltd., along with its principals Dr. Finian Tan and Christopher Michael Ho, have disclosed beneficial ownership of significant portions of Aardvark Therapeutics, Inc.'s common stock, with Vickers Pte holding 9.58%.